Fortress Biotech Q3 net revenue up 20.5% to $17.6M; net income $3.7M vs prior loss

Fortress Biotech, Inc.

2025-Q3 EPS reported $0.14 revenue$47,183,000

Net revenue $17.6M (Q3 2025) vs $14.6M (Q3 2024), driven by dermatology product sales.
Net income attributable to common stockholders $3.7M ($0.13 basic EPS) vs net loss of $15.0M in Q3 2024.
Cash and equivalents $86.2M as of Sep 30, 2025, up from $57.3M at Dec 31, 2024.
Checkpoint sale to Sun Pharma closed May 2025; Fortress received ~$28M upfront plus up to $4.8M CVR and 2.5% royalty on UNLOXCYT sales.
Dotinurad Phase 3 trials dosed Oct 2025; Crystalys raised $205M Series A; Urica (Fortress sub) holds equity and 3% royalty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.